Myelodysplastic Syndromes News and Research

RSS
New technology could hold key to predicting outcome of blood cancer patients

New technology could hold key to predicting outcome of blood cancer patients

Common drug for autoimmune disease may increase risk of myeloid neoplasms

Common drug for autoimmune disease may increase risk of myeloid neoplasms

Researchers design antibody that recognizes and destroys blood cancer stem cells

Researchers design antibody that recognizes and destroys blood cancer stem cells

Combination treatment produces better outcomes in erythropoietin-refractory MDS patients, study shows

Combination treatment produces better outcomes in erythropoietin-refractory MDS patients, study shows

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

The National MDS Study aims to identify causes, genetic makeup of fatal blood diseases

The National MDS Study aims to identify causes, genetic makeup of fatal blood diseases

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers take a giant leap in detecting early stages of leukemia

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

UCSD researchers suggest that cancer-related mutations common in patients with low blood counts

UCSD researchers suggest that cancer-related mutations common in patients with low blood counts

Self-reported fatigue predicts myelodysplastic syndromes survival

Self-reported fatigue predicts myelodysplastic syndromes survival

Researchers identify druggable target to potentially root out colon cancer, end relapse

Researchers identify druggable target to potentially root out colon cancer, end relapse

Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients

Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

MD Anderson researchers discover link between telomere degeneration and MDS

MD Anderson researchers discover link between telomere degeneration and MDS

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Moffitt announces development of innovative investigational biologic agent for MDS

Moffitt announces development of innovative investigational biologic agent for MDS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.